Search En menu en ClientConnect
Search
Results
Top 5 search results See all results Advanced search
Top searches
Most visited pages

    Signature(s)

    Amount
    € 15,000,000
    Countries
    Sector(s)
    Italy : € 15,000,000
    Services : € 15,000,000
    Signature date(s)
    13/12/2019 : € 7,500,000
    13/12/2019 : € 7,500,000
    Link to source
    Data sheet

    Summary sheet

    Release date
    23 December 2019
    Status
    Reference
    Signed | 13/12/2019
    20190151
    Project name
    Promoter - financial intermediary
    MOLMED (EGFF)
    MOLECULAR MEDICINE SPA
    Proposed EIB finance (Approximate amount)
    Total cost (Approximate amount)
    EUR 15 million
    EUR 35 million
    Location
    Sector(s)
    • Services - Professional, scientific and technical activities
    Description
    Objectives

    The Project will finance the RDI activities of the Promoter to develop innovative anti-cancer and rare diseases treatments in the field of cell and gene therapy, during the investment period 2019-2022.

    The proposed transaction will accelerate the Promoter's RDI activities in the strategic and innovative scientific field of gene therapy. By co-investing in the project, the Bank contributes to the advancement in the field of anti-cancer and treatments for rare diseases, whilst also fostering the generation of European knowledge and acumen.

    Environmental aspects
    Procurement

    The project mainly concerns activities that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an Environmental Impact Assessment (EIA) under the Directive 2014/52/EU, amending Directive 2011/92/EU. Nevertheless, the Bank's services will review during the project appraisal whether any of the investments require an EIA, as well as any other environmental details of the project.

    The promoter has been assessed by EIB as being a listed company not operating in the utilities sector and not having a status of a contracting entity, thus not being subject to EU rules on public procurement. However, if after the project appraisal, the EIB were to conclude that the promoter is after all subject to EU public procurement legislation (i.e. Directive 2014/24/EU), then the Bank would require the promoter to ensure that contracts for the implementation of the project will be tendered in accordance with the relevant applicable EU procurement legislation (Directive 2014/24/EU and Directive 89/665/EEC), with publication of tender notices in the EU Official Journal, as and where required.

    Comments

    Considering Molmed is a listed Company, publication and communication of the Project (among others, on website) can be performed only when the Finance Contract is signed.

    Link to source
    Summary sheet

    Disclaimer

    Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
    They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).

    Documents

    Environmental and Social Data Sheet (ESDS) - MOLMED (EGFF)
    Publication Date
    30 May 2020
    Document language
    Main Topic
    Lending
    Document Number
    122878087
    Document Focus
    Environmental Information
    Project Number
    20190151
    Sector(s)
    Regions
    Countries
    Publicly available
    Download now
    scoreboard - EUROPEAN GROWTH FINANCE FACILITY
    Publication Date
    13 Sep 2019
    Document Language
    English
    Main Topic
    lending
    Document Number
    122912044
    Document Focus
    EFSI legal requirements
    Document Type
    Scoreboard
    Project Number
    20200330
    Last update
    19 Aug 2020
    Sector(s)
    Services
    Countries
    France
    Publicly available
    Download now

    News & Stories

    General enquiries and comments

    The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities.
    Enquiries and comments concerning the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.
    Alternatively, the EIB can be contacted through its external offices.
    Queries regarding details of a specific project, in particular when it is under appraisal by the EIB, should preferably be addressed directly to project promoters.

    Media enquiries

    Media-related enquiries can be addressed to the EIB Press Office. Please also visit our Media information section.

    Complaints mechanism

    Any complaint regarding alleged maladministration can be lodged via the EIB Complaints Mechanism. The European Ombudsman acts as an independent external accountability mechanism of the EIB.

    Zero tolerance against fraud and corruption

    The EIB has a zero tolerance policy on fraud or corruption. To report allegations of fraud and corruption relating to EIB-financed projects, please contact the Fraud and Investigation division. All complaints will be treated as strictly confidential and handled in line with the EIB investigation procedures and the Anti-Fraud Policy.

    Related publications